Skip to main content
. 2009 Jul 24;17(2):73–79. doi: 10.1038/cgt.2009.50

Figure 5.

Figure 5

Antitumoral efficacy of i.v. vvDD and JX-963 in VX2 tumor model. (a) Growth curves of primary hepatic tumors in groups treated i.v. with vvDD, JX-963 or phosphate-buffered saline (PBS; control). (b) Antitumoral efficacy against lung metastases (week 8 after tumor implantation) for groups treated i.v. with vvDD, JX-963 or PBS (control). (c) Kaplan–Meier survival curves for overall survival of treatment groups.